Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design

Keyphrases

• Baseline Characteristics 100%
• Exercise Capacity 100%
• Safety Efficacy 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Aficamten 100%
• Clinical Trials 20%
• Placebo 20%
• Hospitalization Rate 20%
• Mortality Rate 20%
• Functional Capacity 20%
• Sudden Death 20%
• Standard of Care 20%
• Health-related Quality of Life 20%
• Functional Symptoms 20%
• Arrhythmia 20%
• Potential Therapy 20%
• Ethnically Diverse Populations 20%
• Symptom Burden 20%
• Phase II Trial 20%
• CA Model 20%
• Heart Failure Death 20%
• Residual Symptoms 20%
• Contemporary Management 20%
• Clinical Trial Design 20%
• Functional Burden 20%
• Impaired Exercise Capacity 20%

Medicine and Dentistry

• Exercise 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Obstruction 100%
• Symptom 60%
• Clinical Trial 40%
• Quality of Life 20%
• Apoplexy 20%
• Placebo 20%
• Functional Status 20%
• Mortality Rate 20%
• Drug Therapy 20%
• Heart Failure 20%
• Sudden Death 20%
• Cardiac Dysrhythmia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Obstruction 100%
• Hypertrophic Obstructive Cardiomyopathy 100%
• Symptom 60%
• Clinical Trial 40%
• Placebo 20%
• Mortality Rate 20%
• Heart Failure 20%
• Functional Status 20%
• Sudden Death 20%
• Heart Arrhythmia 20%